MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma

Su,Zhengming; Chen,Duqun; Zhang,Enpu; Li,Yifan; Yu,Zuhu; Shi,Min; Jiang,Zhimao; Ni,Liangchao; Yang,Shangqi; Gui,Yaoting; Ye,Jiongxian; Lai,Yongqing

doi:10.3892/mmr.2015.3498

MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma

Authors:
- Zhengming Su
- Duqun Chen
- Enpu Zhang
- Yifan Li
- Zuhu Yu
- Min Shi
- Zhimao Jiang
- Liangchao Ni
- Shangqi Yang
- Yaoting Gui
- Jiongxian Ye
- Yongqing Lai
View Affiliations

Affiliations: Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China
Published online on: March 17, 2015 https://doi.org/10.3892/mmr.2015.3498
Pages: 1535-1543

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNAs (miRNAs; miR) are a class of small non-coding RNA molecules, which are involved in the pathogenesis of human diseases through the negative regulation of gene expression. Previous studies have demonstrated that miR‑509‑3p is a novel miRNA associated with cell proliferation and migration in 786‑O renal cell carcinoma (RCC) cells. However, the mechanism of action of miR‑509‑3p in RCC remains to be elucidated. The present study aimed to examine the functional role and mechanism of miR‑509‑3p in the development of RCC. The results demonstrated that the expression levels of miR‑509‑3p were downregulated in the 786‑O and ACHN RCC cell lines compared with the normal tissues of 10 patients with RCC, as determined by reverse transcription‑quantitative polymerase chain reaction. The mRNA expression levels of mitogen‑activated protein kinase kinase kinase 8 (MAP3K8) were upregulated in the RCC cell lines. Functional investigations demonstrated that the overexpression of miR‑509‑3p inhibited the migration and proliferation of the RCC cells, as determined by wound scratch and 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide assays. Luciferase reporter assays revealed that the overexpression of miR‑509‑3p reduced the transcriptional activity of MAP3K8. Furthermore, the present study demonstrated that the ectopic transfection of miR‑509‑3p led to a significant reduction in the mRNA and protein expression levels of MAP3K8 in the RCC cells. Finally, knockdown of MAP3K8 inhibited the migration and proliferation of the RCC cells. Therefore, the results of the present study demonstrated that the miR‑509‑3p RCC suppressor was a significant regulator of the MAP3K8 oncogene, suggesting that it may have a potential therapeutic role in the treatment of RCC.

View Figures

View References

1	Yamada Y, Hidaka H, Seki N, et al: Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma. Cancer Sci. 104:304–312. 2013. View Article : Google Scholar
2	Mulders PF, Brouwers AH, Hulsbergen-van der Kaa CA, van Lin EN, Osanto S and de Mulder PH: Guideline ‘Renal cell carcinoma’. Ned Tijdschr Geneeskd. 152:376–380. 2008.in Dutch. PubMed/NCBI
3	Hadoux J, Vignot S and De La Motte Rouge T: Renal cell carcinoma: Focus on safety and efficacy of temsirolimus. Clin Med Insights Oncol. 4:143–154. 2010. View Article : Google Scholar
4	Patel C, Ahmed A and Ellsworth P: Renal cell carcinoma: A reappraisal. Urol Nurs. 32:182–190; quiz. 1912012.PubMed/NCBI
5	Yu ZH, Zhang Q, Wang YD, et al: Overexpression of cyclooxygenase-1 correlates with poor prognosis in renal cell carcinoma. Asian Pac J Cancer Prev. 14:3729–3734. 2013. View Article : Google Scholar : PubMed/NCBI
6	Janzen NK, Kim HL, Figlin RA and Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
7	Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM and Ghobrial IM: Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 1845:255–265. 2014.PubMed/NCBI
8	Xi Y: MicroRNA: A new player for cancer chemoprevention. J Integr Oncol. 2:1052013. View Article : Google Scholar : PubMed/NCBI
9	Lu R, Ji Z, Li X, Zhai Q, Zhao C, Jiang Z, Zhang S, Nie L and Yu Z: miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J Cancer Res Clin Oncol. 140:387–397. 2014. View Article : Google Scholar : PubMed/NCBI
10	Yu Z, Ni L, Chen D, et al: Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013. View Article : Google Scholar : PubMed/NCBI
11	Peng H, Luo J, Hao H, Hu J, Xie SK, Ren D and Rao B: MicroRNA-100 regulates SW620 colorectal cancer cell proliferation and invasion by targeting RAP1B. Oncol Rep. 31:2055–2062. 2014.PubMed/NCBI
12	Xie J, Chen M, Zhou J, Mo MS, Zhu LH, Liu YP, Gui QJ, Zhang L and Li GQ: miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. Oncol Rep. 31:1715–1722. 2014.PubMed/NCBI
13	Salmeron A, Ahmad TB, Carlile GW, Pappin D, Narsimhan RP and Ley SC: Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. EMBO J. 15:817–826. 1996.PubMed/NCBI
14	Krcova Z, Ehrmann J, Krejci V, Eliopoulos A and Kolar Z: Tpl-2/Cot and COX-2 in breast cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 152:21–25. 2008. View Article : Google Scholar : PubMed/NCBI
15	Jeong JH, Bhatia A, Toth Z, Oh S, Inn KS, Liao CP, Roy-Burman P, Melamed J, Coetzee GA and Jung JU: TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth. PLoS One. 6:e162052011. View Article : Google Scholar : PubMed/NCBI
16	Aparecida Alves C, Silva ID, Villanova FE, Nicolau SM, Custódio MA, Bortoletto C and Gonçalves WJ: Differential gene expression profile reveals overexpression of MAP3K8 in invasive endometrioid carcinoma. Eur J Gynaecol Oncol. 27:589–593. 2006.
17	Tunca B, Tezcan G, Cecener G, et al: Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients. J Cancer Res Clin Oncol. 139:691–702. 2013. View Article : Google Scholar : PubMed/NCBI
18	Martínez-Salamanca JI, Huang WC, Millan I, et al: Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol. 59:120–127. 2011. View Article : Google Scholar Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
19	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
20	Zhai Q, Zhou L, Zhao C, Wan J, Yu Z, Guo X, Qin J, Chen J and Lu R: Identification of miR-508-3p and miR-509-3p that are associated with cell invasion and migration and involved in the apoptosis of renal cell carcinoma. Biochem Biophys Res Commun. 419:621–626. 2012. View Article : Google Scholar : PubMed/NCBI
21	Li S, Fu H, Wang Y, Tie Y, Xing R, Zhu J, Sun Z, Wei L and Zheng X: MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology. 49:1194–1202. 2009. View Article : Google Scholar : PubMed/NCBI
22	Song T, Zhang X, Wang C, Wu Y, Cai W, Gao J and Hong B: MiR-138 suppresses expression of hypoxia-inducible factor 1α (HIF-1α) in clear cell renal cell carcinoma 786-O cells. Asian Pac J Cancer Prev. 12:1307–1311. 2011.
23	Neal CS, Michael MZ, Rawlings LH, Van der Hoek MB and Gleadle JM: The VHL-dependent regulation of microRNAs in renal cancer. BMC Med. 8:642010. View Article : Google Scholar : PubMed/NCBI
24	Saini S, Yamamura S, Majid S, Shahryari V, Hirata H, Tanaka Y and Dahiya R: MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res. 71:6208–6219. 2011. View Article : Google Scholar : PubMed/NCBI
25	Yu XY, Zhang Z, Liu J, Zhan B and Kong CZ: MicroRNA-141 is downregulated in human renal cell carcinoma and regulates cell survival by targeting CDC25B. Onco Targets Ther. 6:349–354. 2013.PubMed/NCBI
26	Johannessen CM, Boehm JS, Kim SY, et al: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 468:968–972. 2010. View Article : Google Scholar : PubMed/NCBI
27	Kim K, Kim G, Kim JY, Yun HJ, Lim SC and Choi HS: Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation. Carcinogenesis. 35:1352–1361. 2014. View Article : Google Scholar : PubMed/NCBI